Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
CA 1340417 C · Owner: Aventis Holdings Inc. · Inventors: Bellot, Francoise; Kris, Richard; Schlessinger, Joseph
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Monoclonal antibodies and hybrid cell lines for production of monoclonal antibodies specific to the human epidermal growth factor receptor which are capable of inhibiting the growth of human tumor cells expressing human epidermal growth factor receptors are provided. Therapeutic compositions containing these monoclonal antibodies by themselves and in combination with anti-neoplastic agents are also disclosed.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Granted March 2, 1999. A Canadian patent filed before October 1, 1989 lasted 17 years from grant, so its term ended March 2, 2016.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.